An analysis of the ZIRCON trial, presented at the Society of Urologic Oncology's annual meeting, found that 89Zr-girentuximab PET/CT would have led to changes in clinical management for 48.6% of patients with indeterminate renal masses, compared with conventional imaging. Dr. Brian Shuch noted that more than 20% of patients could have potentially avoided a biopsy.

Using the #1 ordered PSMA PET imaging agent in the US brings greater clarity than conventional imaging and improves disease assessment. Discover how this may benefit your appropriate patients. Click here.

A literature review presented at the RSNA conference found PSMA PET/CT may be more effective than MRI in staging high-risk prostate cancer. PSMA PET/CT was found to have higher sensitivity and specificity in detecting lymph node metastasis, as well as a lower rate of under-staging compared with MRI.

A Phase 1 trial published in a radiology journal found promising results for a new copper-61-labeled PET imaging agent in detecting metastatic prostate cancer lesions. Researchers found the agent was well-tolerated, with no adverse events, and its half-life of 3.3 hours offers improved tracer biodistribution and greater image resolution.

The FDA approved an investigational drug exemption to allow a pilot study of Alpha DaRT, an alpha-radiation therapy using radium-224 that is designed to treat tumors while preserving healthy tissue. The trial will enroll up to 12 patients with locally recurrent prostate cancer.

Theranostics combines diagnostics and therapy, using molecular imaging to identify the biological target the drug is designed to treat, said Sergio Calvo, global general manager of theranostics at GE Healthcare. Calvo said theranotics will "grow 20-fold" over the next decade, and while hospitals are investing in it, there needs to be significant infrastructure added to scale its use.

A new American Hospital Association report based on data from Vizient shows that survival rates in US hospitals have increased 30% since 2019, central line-associated bloodstream infections have decreased 24%, and urinary tract infections linked to catheters decreased 25%, as of mid-2025. Breast and colon cancer screenings increased 95% over the study period, according to the report.

US Reps. John Joyce, R-Pa., and Scott Peters, D-Calif., have introduced the Health Tech Investment Act, which aims to improve access to AI-enabled medical devices by ensuring payment for innovative technologies. It would give all FDA-approved AI devices a new classification in the hospital outpatient payment system.

Experts at the Food and Drug Law Institute conference have urged the FDA to provide clearer guidance on the regulation of AI and large language models used in drug development and manufacturing. Anthony Schiavone from Agilent Technologies highlighted the fragmented global regulatory landscape, noting the EU's comprehensive AI framework. Tala Fakhouri from Parexel shared that over 800 AI-related submissions have been made to the FDA's Center for Drug Evaluation and Research, mostly in oncology.

Gov. Kathy Hochul has signed a bill eliminating copays for lung cancer screenings, aiming to improve early detection and treatment. The law is expected to benefit high-risk populations by making annual CT scans more accessible. However, the New York Health Plan Association warns that it could increase insurance premiums and overall health care costs.